StemCell Therapy

RUTHERFORD, N.J. and LOS ANGELES, Aug. 16, 2017 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) (The Company and CGI), a leader in enabling precision medicine for oncology through molecular markers and diagnostics, announced todaythat it will host an investor and analyst call and webcast onTuesday,August 22, 2017at8:30 am Eastern. CGI willdiscuss the strategy and business rationale of the recent transformative and accretive acquisition ofvivoPharm.

CGIs acquisition ofvivoPharm, announced on August 14, 2017,will significantly strengthenthe Company's position as a leader for oncology discoveryand early phase clinical development and testing for biotechnology and pharmaceutical companies. With over a decade of experience in delivering a wide range of discovery and preclinical services to support drug development, target validation and biomarker analysis,vivoPharm has supported over 200 IND submissions for innovative therapies, with a significant focus on immuno-oncology.

Hosted by CGI's CEO and President, Mr. Panna Sharma, the call will introduceinvestors and analysts tonew members of the CGI team, including Dr. RalfBrandt, former CEO and Managing Director ofvivoPharm, who now serves as the President of Discovery & Early Development Services at CGI.

Mr. Sharma will also provide insight into both operational and customer synergies that will result from the integration ofvivoPharm, as well as the long-term strategy for growth. Additional details will also be provided onvivoPharms specialized tumor and disease models, toxicology and pharmacology services, biomarker analysis and animal imaging capabilitiesthat are expected toprovide CGInewopportunities to deepen its relationships with existing biopharma customers through additional discovery and downstream molecular work,while bolstering the Companys previously announced initiative aimed at early-phase drug repurposing and drug rescue programs.

The call details are noted in the table below.

ABOUT CANCER GENETICSCancer Genetics, Inc. is a leader in enabling precision medicine in oncology from bench to bedside through the use of oncology biomarkers and molecular testing. CGI is developing a global footprint with locations in the US, India and China. We have established strong clinical research collaborations with major cancer centers such as Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic, Keck School of Medicine at USC and the National Cancer Institute.

The Company offers a comprehensive range of laboratory services that provide critical genomic and biomarker information. Its state-of-the-art reference labs are CLIA-certified and CAP-accredited in the US and have licensure from several states including New York State.

For more information, please visit or follow us:Internet:www.cancergenetics.comTwitter:@Cancer GeneticsFacebook:www.facebook.com/CancerGenetics

Forward Looking Statements:This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in revenues, margins, research, technology, clinical development and potential opportunities for Cancer Genetics, Inc. tests and services, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements.

Any statements that are not historical fact (including, but not limited to, statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, risks of cancellation of customer contracts or discontinuance of trials, risks that anticipated benefits from acquisitions will not be realized, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, maintenance of intellectual property rights and other risks discussed in the Cancer Genetics, Inc. Form 10-K for the year ended December 31, 2016 along with other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics, Inc. disclaims any obligation to update these forward-looking statements.

Read this article:
Cancer Genetics, Inc. to Host Conference Call to Discuss Strategic and Business Rationale of vivoPharm Acquisition - GlobeNewswire (press release)

This entry was posted on August 16, 2017 at 10:46 am and is filed under Molecular Genetics. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |